All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bcl-2 is a pro-survival oncogene that promotes leukemogenesis by blocking programmed cell death. Therefore, agents designed to disrupt proteins that are involved in anti-apoptotic pathways are considered for MDS therapy, including Bcl-2 inhibitors like venetoclax. For other pro-apoptotic proteins, like 'BH3-only' proteins, BH3 agonists are in development.